secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-09-18T21:11:43+00:00
Accession:  0001213900-26-101492
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed receives Nasdaq delisting notice for equity shortfall; merger to cure
---------------------------------------------------------------------------

- Nasdaq notice on 9/16/2026: shareholders' equity $1,075,007 vs $2.5M required under Rule 5550(b)(1).
- 45 days to submit compliance plan (by Nov 2, 2026); up to 180-day extension possible until Mar 15, 2027.
- Deficiency driven by Merger expenses with Mentari; combined company expects ~$490M gross proceeds, closing Q4 2026.
- Stock up ~99.8% since Merger announcement; shares continue trading on Nasdaq under INM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/0001213900-26-101492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/ea0305769-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-101492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer